Key Dates

Related Announcements

NOT-ES-20-018 - Notice of Special Interest: Promoting Fundamental and Applied Research in Inflammation Resolution

PA-20-183 - Research Project Grant (Parent R01 Clinical Trial Required)

PA-20-185 - Research Project Grant (Parent R01 Clinical Trial Not Allowed)

Issued by

National Institute of General Medical Sciences (NIGMS)

Purpose

The purpose of this Notice is to indicate NIGMS' participation in NOT-ES-20-018 "Notice of Special Interest: Promoting Fundamental and Applied Research in Inflammation Resolution".

NIGMS will accept applications on fundamental research into the mechanisms of inflammation resolution. The Institute has a long-standing interest in basic and clinical studies of injury and critical illness, and associated mechanisms of wound healing. Injury and trauma cause acute inflammation via damage-associated molecular patterns (DAMP). Inflammation may either facilitate debris clearance or lead to further tissue injury, depending on the scale of the inflammation cascade and/or the proper resolution of inflammation. Chronic inflammation has also been shown to critically impact the recovery and resolution process. Unraveling basic mechanisms of inflammation resolution in the context of trauma, burn, peri-operative injury, sepsis, and recovery would contribute significantly to understanding the pathogenesis of these conditions.

This NOSI encourages, but is not limited to, research applications in the following areas, when applied within the NIGMS mission areas (injury and critical illness, sepsis, post-injury tissue repair and wound healing):

• Molecular mechanisms that activate, escalate, or suppress the production of inflammatory resolution factors;
• Interactions between mediators of inflammation resolution and pathways that determine innate and adaptive immunity;
• Regulation by inflammation resolution factors of phagocytosis or efferocytosis functions of phagocytes, as well as the effector-producing function of innate immune cells;
• Relationship of inflammation resolution factors to known contributors to critical illness, including elevated or systemic inflammation and immunosuppression;
• Clinical studies that explore the contribution of inflammation resolution factors to pathways that determine the progression, trajectory, and outcomes for critically ill patients.

NIGMS will consider the following to be non-responsive to this NOSI: disease-specific applications relevant to other ICs at NIH, toxicant exposure-induced inflammatory mechanisms. NIGMS will only consider studies using rodent models with compelling justification that they reflect events in human inflammatory processes. The Notice of NIGMS Sepsis Research Priorities applies to all applications with a sepsis focus. Posted NIGMS clinical trial considerations and limitations apply to all R01 applications with a clinical trial component.

NIGMS will accept responsive applications submitted to PA-20-183 and PA-20-185.

The FOA table in the NOSI is updated accordingly, by adding NIGMS (shown in italic below) where appropriate.

All other aspects of the NOSI remain the same.

Inquiries

Please direct all inquiries to:

Xiaoli Zhao, Ph.D.
National Institute of General Medical Sciences (NIGMS)
Email: xiaoli.zhao@nih.gov